Individualizing renal cell carcinoma treatment through biomarkers discovery in the era of immune checkpoint inhibitors: where do we stand?

Camillo Porta, Laura Cosmai, Mimma Rizzo

Research output: Contribution to journalReview articlepeer-review

Abstract

PURPOSE OF REVIEW: The treatment landscape of metastatic renal cell carcinoma has greatly evolved over the past fifteen years, leading to a significant improvement in the outcome of our patients. However, there is still an urgent need for predictive biomarkers that could guide our treatment selection, especially in the present era of immune-based treatments.

RECENT FINDINGS: A number of putative biomarkers of immunotherapy activity have been proposed over the past few years, including PD-L1 immunohistochemical expression, tumor mutational burden, neoantigens load, insertions and deletions, complex gene signatures, as well as lymphocytic subpopulations (either circulating or tumor-infiltrating). However, despite preliminary intriguing findings, no biomarker for immune checkpoint activity has emerged so far, that could be used in everyday clinical practice, mainly due to preliminary, or frankly, conflicting results.

SUMMARY: The quest for an 'ideal' biomarker, which should be characterized by adequate specificity, sensibility, predictive (and not just prognostic) value, robustness, reproducibility, ease of evaluation and low cost, is still ongoing.

Original languageEnglish
Pages (from-to)236-241
Number of pages6
JournalCurrent Opinion in Urology
Volume31
Issue number3
DOIs
Publication statusPublished - May 1 2021

Keywords

  • Biomarkers, Tumor/genetics
  • Carcinoma, Renal Cell/drug therapy
  • Humans
  • Immune Checkpoint Inhibitors
  • Immunotherapy
  • Kidney Neoplasms/drug therapy
  • Reproducibility of Results

Fingerprint

Dive into the research topics of 'Individualizing renal cell carcinoma treatment through biomarkers discovery in the era of immune checkpoint inhibitors: where do we stand?'. Together they form a unique fingerprint.

Cite this